Form 4: RxSight CFO Wilterding Boosts Stake with New Equity Grants

RxSight, Inc. Chief Financial Officer Mark Wilterding received grants of 258,770 stock options and 163,528 restricted stock units, aligning his interests with long-term shareholder value.

Summary

• Mark Wilterding, Chief Financial Officer of RxSight, Inc. (RXST), was granted 258,770 stock options on January 12, 2026.
• The stock options have an exercise price of $10.09 per share and an expiration date of January 11, 2036.
• The stock options vest 25% on January 11, 2027 (one-year anniversary of the Vesting Commencement Date of January 11, 2026), with the remaining shares vesting equally monthly over the subsequent three years, fully vesting four years from the Vesting Commencement Date.
• Wilterding also received 163,528 Restricted Stock Units (RSUs) on January 12, 2026.
• Each RSU represents a contingent right to receive one share of RxSight's Common Stock.
• The RSUs vest 1/8th on February 28, 2026, and then 1/8th every six months thereafter on the last day of February and August over a four-year period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily because it strengthens the alignment of the CFO's financial interests with long-term shareholder value, which is generally beneficial for corporate governance and performance incentives.

Positives

• The equity grants align the Chief Financial Officer's long-term financial interests with those of shareholders, incentivizing sustained company performance.
• The significant number of options and RSUs demonstrates a commitment to retaining key management personnel.

Negatives

• The future exercise of stock options and vesting of RSUs could lead to a minor dilutive effect on existing shareholders, although this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is subject to the future market price of RxSight's common stock, meaning they could be worthless if the stock price does not exceed the exercise price.
• Vesting of both the stock options and RSUs is contingent upon the reporting person continuing to be a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan, posing a risk of forfeiture if employment terms are not met.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an executive's equity compensation grants.

Industry Context

StockSavvy.ai notes that the granting of stock options and restricted stock units to key executives like the Chief Financial Officer is a standard practice across various industries, particularly in growth-oriented sectors such as medical technology. This form of compensation is designed to align management incentives with long-term shareholder value creation and is a common component of competitive executive compensation packages.

Comparison to Industry Standards

• The use of a combination of stock options and Restricted Stock Units (RSUs) is a common executive compensation strategy, similar to practices at peer companies in the medical device and biotechnology sectors like Alcon (ALC) or Bausch + Lomb (BLCO).
• The four-year vesting schedules for both options and RSUs are typical for executive equity grants, aiming to promote long-term retention and performance, consistent with industry benchmarks.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon exercise of options and vesting of RSUs, but also increased alignment of executive incentives with shareholder returns.
• Employees: The grants reflect standard executive compensation practices, which can indirectly influence overall compensation philosophy within the company.

Next Steps

• Continued service by the Chief Financial Officer to meet vesting conditions for both stock options and RSUs.
• Periodic vesting of stock options on a monthly basis following January 11, 2027, until fully vested by January 11, 2030.
• Periodic vesting of RSUs every six months on the last day of February and August until fully vested by August 31, 2029.

Key Dates

Recommendation

This Form 4 reports routine equity compensation grants to a key executive. While it indicates continued commitment and alignment of management interests with shareholders, it does not present new information significant enough to warrant a change in investment recommendation. Such grants are standard practice and do not typically signal an immediate 'buy' or 'sell' opportunity.

Keywords

RxSight, RXST, Stock Option, Restricted Stock Unit, RSU, Insider Transaction, Executive Compensation, CFO, Equity Incentive Plan, Vesting Schedule